Affinity Asset Advisors, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Affinity Asset Advisors, LLC reported 78 stock positions worth $576.0 million. Its top holding was Xenon Pharmaceuticals (XENE) at 6.7% of the portfolio, followed by Apogee Therapeutics (APGE, 5.7%) and Madrigal Pharmaceuticals (MDGL, 5.4%). Compared with Q1 2024, it opened 25 new positions, sold out of 16, added to 29 and reduced 16. The biggest buy was Alkermes (ALKS, shares +767%) and the biggest sale an exit from Apellis Pharmaceuticals (APLS).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001773195
- Portfolio Value
- $576.0M (Q2 2024)
- SEC Filing
- 0001999371-24-010146 ↗ filed Aug 14, 2024
Holdings Value
Holdings 78 stocks · $576.0M
| XENE Xenon Pharmaceuticals Inc. | 6.73% | 994,227 | $38.8M | Add +18.7% |
| APGE Apogee Therapeutics Inc. | 5.71% | 836,283 | $32.9M | Add +41.2% |
| MDGL Madrigal Pharmaceuticals Inc. | 5.35% | 110,000 | $30.8M | Reduce -4.3% |
| ACLX Arcellx Inc. | 4.41% | 460,000 | $25.4M | Add +53.3% |
| TEVA Teva Pharmaceutical-SP ADR | 4.09% | 1,450,000 | $23.6M | Add +3.6% |
| CRNX Crinetics Pharmaceuticals Inc. | 4.00% | 515,000 | $23.1M | Add +9.6% |
| CERE Cerevel Therapeutics Holding | 3.55% | 500,000 | $20.4M | Add +66.7% |
| NRIX Nurix Therapeutics Inc. | 3.30% | 912,000 | $19.0M | Add +12.6% |
| CLDX Celldex Therapeutics Inc. | 3.05% | 475,400 | $17.6M | Reduce -6.8% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 2.72% | 110,000 | $15.7M | Add +33.9% |
| ALKS Alkermes PLC | 2.72% | 650,000 | $15.7M | Add +766.7% |
| NUVL Nuvalent Inc. Class A | 2.63% | 200,000 | $15.2M | Add +33.3% |
| AUTL Autolus Therapeutics PLC | 2.60% | 4,300,000 | $15.0M | Add +27.4% |
| VERA Vera Therapeutics Inc. | 2.36% | 375,000 | $13.6M | Reduce -20.2% |
| KURA Kura Oncology Inc. | 2.32% | 650,000 | $13.4M | Reduce -11.0% |
| INZY Inozyme Pharma Inc. | 2.21% | 2,856,252 | $12.7M | Add +8.1% |
| SYRE Spyre Therapeutics Inc. | 2.10% | 513,420 | $12.1M | Add +25.2% |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 2.06% | 1,670,661 | $11.9M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.78% | 1,135,702 | $10.3M | Add +36.7% |
| ESTA Establishment Labs Holdings | 1.76% | 223,407 | $10.2M | Add +35.7% |
| VRNA Verona Pharma Ltd. | 1.76% | 700,000 | $10.1M | Reduce -14.4% |
| NARI Inari Medical Inc. | 1.67% | 200,000 | $9.6M | Add +14.3% |
| IMVT Immunovant Inc. | 1.59% | 346,088 | $9.1M | Add +21.4% |
| ATXS Astria Therapeutics Inc. | 1.54% | 975,606 | $8.9M | Add +15.4% |
| MORF Morphic Holding Inc. | 1.48% | 250,573 | $8.5M | Add +11.4% |
| INSM Insmed Inc. | 1.45% | 125,000 | $8.4M | New |
| NAMS Newamsterdam Pharma Co. NV | 1.41% | 423,155 | $8.1M | Add +47.9% |
| RZLT Rezolute Inc. | 1.38% | 1,850,000 | $8.0M | Add +15.6% |
| MRUS Merus NV | 1.28% | 125,000 | $7.4M | New |
| AXSM Axsome Therapeutics Inc. | 1.12% | 80,000 | $6.4M | Reduce -42.8% |
| GERN Geron Corp. | 1.10% | 1,500,000 | $6.4M | Reduce -40.0% |
| SVRA Savara Inc. | 1.08% | 1,546,850 | $6.2M | Add +34.5% |
| ERAS Erasca Inc. | 1.02% | 2,499,431 | $5.9M | New |
| CATX Perspective Therapeutics Inc. | 0.95% | 550,000 | $5.5M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.92% | 155,000 | $5.3M | Reduce -3.1% |
| CGEM Cullinan Therapeutics Inc. | 0.80% | 263,817 | $4.6M | Add +2.0% |
| PCVX Vaxcyte Inc. | 0.79% | 60,000 | $4.5M | Reduce -25.0% |
| ELEV Elevation Oncology Inc. | 0.69% | 1,468,825 | $4.0M | Add +15.8% |
| HLVX Hillevax Inc. | 0.67% | 265,859 | $3.8M | New |
| MLYS Mineralys Therapeutics Inc. | 0.67% | 327,959 | $3.8M | No change |
| ROIV Roivant Sciences Ltd. | 0.65% | 351,587 | $3.7M | Reduce -29.7% |
| DYN Dyne Therapeutics Inc. | 0.61% | 100,000 | $3.5M | New |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.61% | 350,000 | $3.5M | New |
| IMTX Immatics NV | 0.61% | 300,000 | $3.5M | Reduce -14.3% |
| XBI SS SPDR S&P Biotech ETF | 0.60% | 37,550 | $3.5M | New |
| CNTX Context Therapeutics Inc. | 0.56% | 1,619,140 | $3.2M | Add +392.4% |
| BDTX Black Diamond Therapeutics I | 0.53% | 650,000 | $3.0M | New |
| CMPS Compass Pathways PLC | 0.52% | 500,512 | $3.0M | Reduce -51.3% |
| OLMA Olema Pharmaceuticals Inc. | 0.52% | 275,000 | $3.0M | New |
| NXTC Nextcure Inc. | 0.47% | 1,687,955 | $2.7M | Add +24.2% |
| SWTX Springworks Therapeutics Inc. | 0.46% | 69,999 | $2.6M | Reduce -30.0% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.44% | 250,000 | $2.6M | No change |
| BBIO Bridgebio Pharma Inc. | 0.44% | 100,000 | $2.5M | Add +100.0% |
| VRDN Viridian Therapeutics Inc. | 0.34% | 150,000 | $2.0M | New |
| WVE Wave Life Sciences Ltd. | 0.32% | 375,000 | $1.9M | Add +30.9% |
| VIR Vir Biotechnology Inc. | 0.31% | 200,000 | $1.8M | New |
| ZYME Zymeworks Inc. | 0.28% | 191,127 | $1.6M | New |
| MERSANA THERAPEUTICS INC | 0.27% | 767,000 | $1.5M | Reduce -23.3% |
| ARYD Arya Sciences Acquisition-A | 0.27% | 133,500 | $1.5M | No change |
| ADCT Adc Therapeutics SA | 0.26% | 474,744 | $1.5M | New |
| KYTX Kyverna Therapeutics Inc. | 0.26% | 200,000 | $1.5M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.23% | 50,000 | $1.3M | Reduce -58.3% |
| TNGX Tango Therapeutics Inc. | 0.22% | 150,274 | $1.3M | No change |
| NKTX Nkarta Inc. | 0.21% | 200,000 | $1.2M | New |
| KEZAR LIFE SCIENCES INC | 0.18% | 1,761,778 | $1.1M | No change |
| TECX Tectonic Therapeutic Inc. | 0.17% | 58,331 | $961K | New |
| PBYI Puma Biotechnology Inc. | 0.14% | 250,000 | $815K | New |
| ZURA Zura Bio Ltd. | 0.14% | 223,335 | $782K | Reduce -50.4% |
| AVTX Avalo Therapeutics Inc. | 0.10% | 45,000 | $561K | Add +350.0% |
| QTTB Q32 Bio Inc. | 0.09% | 27,777 | $499K | No change |
| MTVA Metavia Inc. filed as NEUROBO PHARMACEUTICALS INC | 0.07% | 89,222 | $432K | New |
| PMN Promis Neurosciences Inc. | 0.07% | 265,958 | $399K | No change |
| AEROVATE THERAPEUTICS INC | 0.06% | 200,000 | $332K | New |
| ARCA BIOPHARMA INC | 0.05% | 72,484 | $278K | New |
| RAPT THERAPEUTICS INC | 0.04% | 75,000 | $229K | New |
| PASG Passage Bio Inc. | 0.04% | 264,266 | $210K | No change |
| GNLX Genelux Corp. | 0.03% | 100,000 | $195K | New |
| IOVA Iovance Biotherapeutics Inc. | 0.00% | 100 | $802 | New |
Options reported separately and not counted above: SPY puts ($190.5M), TEVA calls ($18.7M), CERE calls ($10.2M), SANA puts ($2.8M), TWST calls ($2.2M), RAPT THERAPEUTICS INC puts ($1.7M), FULC calls ($1.6M), IMVT calls ($1.4M), IOVA puts ($1.2M), PCVX calls ($1.1M), ALXO calls ($603K), INSM puts ($583K).
Other holdings (8): bonds, preferreds, convertibles and warrants · $58.9M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 17,000,000 | $17.3M | No change |
| ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27) | NOTE 1.000% 9/1 · principal | 15,000,000 | $16.2M | Add +50.0% |
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | 11,750,000 | $8.6M | Add +30.6% |
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | 11,450,000 | $8.1M | Add +9.1% |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | 9,750,000 | $6.3M | New |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 202,599 | $1.9M | No change |
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | 187,204 | $485K | No change |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 75,000 | $5K | No change |
Total filed on the 13F, all lines: $634.9M.
Portfolio Sells Q1 2024 → Q2 2024
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −1.70 |
| VERA Vera Therapeutics Inc. | Reduce -20.2% | 2.36% | −1.19 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −1.06 |
| ABSI Absci Corp. | Sold out | 0.00% | −1.02 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.98 |
| CMPS Compass Pathways PLC | Reduce -51.3% | 0.52% | −0.97 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.91 |
| AXSM Axsome Therapeutics Inc. | Reduce -42.8% | 1.12% | −0.83 |
| KRYS Krystal Biotech Inc. | Sold out | 0.00% | −0.83 |
| VKTX Viking Therapeutics Inc. | Sold out | 0.00% | −0.72 |
| CLDX Celldex Therapeutics Inc. | Reduce -6.8% | 3.05% | −0.69 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.66 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −0.61 |
| VRNA Verona Pharma Ltd. | Reduce -14.4% | 1.76% | −0.55 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.52 |
| MERSANA THERAPEUTICS INC | Reduce -23.3% | 0.27% | −0.52 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| RGNX Regenxbio Inc. | Sold out | 0.00% | −0.41 |
| KURA Kura Oncology Inc. | Reduce -11.0% | 2.32% | −0.41 |
| SWTX Springworks Therapeutics Inc. | Reduce -30.0% | 0.46% | −0.40 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -58.3% | 0.23% | −0.38 |
| GERN Geron Corp. | Reduce -40.0% | 1.10% | −0.34 |
| BSX Boston Scientific Corp. | Sold out | 0.00% | −0.30 |
| ROIV Roivant Sciences Ltd. | Reduce -29.7% | 0.65% | −0.28 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −0.20 |
| PCVX Vaxcyte Inc. | Reduce -25.0% | 0.79% | −0.17 |
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −0.17 |
| AVROBIO INC | Sold out | 0.00% | −0.16 |
| ZURA Zura Bio Ltd. | Reduce -50.4% | 0.14% | −0.07 |
| IMTX Immatics NV | Reduce -14.3% | 0.61% | −0.04 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -4.3% | 5.35% | −0.03 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -3.1% | 0.92% | +0.22 |
Portfolio Buys Q1 2024 → Q2 2024
| ALKS Alkermes PLC | Add +766.7% | 2.72% | +2.36 |
| CLYM Climb Bio Inc. | New | 2.06% | +2.06 |
| INSM Insmed Inc. | New | 1.45% | +1.45 |
| CERE Cerevel Therapeutics Holding | Add +66.7% | 3.55% | +1.33 |
| MRUS Merus NV | New | 1.28% | +1.28 |
| NRIX Nurix Therapeutics Inc. | Add +12.6% | 3.30% | +1.22 |
| ERAS Erasca Inc. | New | 1.02% | +1.02 |
| CATX Perspective Therapeutics Inc. | New | 0.95% | +0.95 |
| ACLX Arcellx Inc. | Add +53.3% | 4.41% | +0.75 |
| HLVX Hillevax Inc. | New | 0.67% | +0.67 |
| RZLT Rezolute Inc. | Add +15.6% | 1.38% | +0.67 |
| NUVL Nuvalent Inc. Class A | Add +33.3% | 2.63% | +0.66 |
| TEVA Teva Pharmaceutical-SP ADR | Add +3.6% | 4.09% | +0.63 |
| DYN Dyne Therapeutics Inc. | New | 0.61% | +0.61 |
| FRNM Freenome Inc. | New | 0.61% | +0.61 |
| XBI SS SPDR S&P Biotech ETF | New | 0.60% | +0.60 |
| BDTX Black Diamond Therapeutics I | New | 0.53% | +0.53 |
| OLMA Olema Pharmaceuticals Inc. | New | 0.52% | +0.52 |
| CNTX Context Therapeutics Inc. | Add +392.4% | 0.56% | +0.48 |
| ONC Beone Medicines Ltd.-ADR | Add +33.9% | 2.72% | +0.47 |
| XENE Xenon Pharmaceuticals Inc. | Add +18.7% | 6.73% | +0.42 |
| VRDN Viridian Therapeutics Inc. | New | 0.34% | +0.34 |
| VIR Vir Biotechnology Inc. | New | 0.31% | +0.31 |
| ESTA Establishment Labs Holdings | Add +35.7% | 1.76% | +0.30 |
| ZYME Zymeworks Inc. | New | 0.28% | +0.28 |
| KYTX Kyverna Therapeutics Inc. | New | 0.26% | +0.26 |
| ADCT Adc Therapeutics SA | New | 0.26% | +0.26 |
| NAMS Newamsterdam Pharma Co. NV | Add +47.9% | 1.41% | +0.23 |
| NKTX Nkarta Inc. | New | 0.21% | +0.21 |
| NARI Inari Medical Inc. | Add +14.3% | 1.67% | +0.20 |
| BBIO Bridgebio Pharma Inc. | Add +100.0% | 0.44% | +0.17 |
| TECX Tectonic Therapeutic Inc. | New | 0.17% | +0.17 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +9.6% | 4.00% | +0.15 |
| PBYI Puma Biotechnology Inc. | New | 0.14% | +0.14 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +36.7% | 1.78% | +0.14 |
| MORF Morphic Holding Inc. | Add +11.4% | 1.48% | +0.10 |
| SVRA Savara Inc. | Add +34.5% | 1.08% | +0.08 |
| MTVA Metavia Inc. | New | 0.07% | +0.07 |
| AVTX Avalo Therapeutics Inc. | Add +350.0% | 0.10% | +0.06 |
| AEROVATE THERAPEUTICS INC | New | 0.06% | +0.06 |
| ARCA BIOPHARMA INC | New | 0.05% | +0.05 |
| RAPT THERAPEUTICS INC | New | 0.04% | +0.04 |
| GNLX Genelux Corp. | New | 0.03% | +0.03 |
| CGEM Cullinan Therapeutics Inc. | Add +2.0% | 0.80% | +0.03 |
| WVE Wave Life Sciences Ltd. | Add +30.9% | 0.32% | +0.02 |
| IOVA Iovance Biotherapeutics Inc. | New | 0.00% | +0.00 |
| IMVT Immunovant Inc. | Add +21.4% | 1.59% | −0.03 |
| NXTC Nextcure Inc. | Add +24.2% | 0.47% | −0.06 |
| ELEV Elevation Oncology Inc. | Add +15.8% | 0.69% | −0.45 |
| ATXS Astria Therapeutics Inc. | Add +15.4% | 1.54% | −0.54 |
Options Activity Q1 2024 → Q2 2024
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 350,000 | $190.5M |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 700,000 | $66.4Mbefore exit |
| MRNA Moderna Inc. | put | Sold out | 400,000 | $42.6Mbefore exit |
| TEVA Teva Pharmaceutical-SP ADR | call | Reduce -30.5% | 1,150,000 | $18.7M |
| CERE Cerevel Therapeutics Holding | call | New | 250,000 | $10.2M |
| IRWD Ironwood Pharmaceuticals Inc. | call | Sold out | 1,029,500 | $9.0Mbefore exit |
| BBIO Bridgebio Pharma Inc. | call | Sold out | 250,000 | $7.7Mbefore exit |
| GRITSTONE BIO INC | put | Sold out | 2,390,600 | $6.1Mbefore exit |
| ALNY Alnylam Pharmaceuticals Inc. | call | Sold out | 40,000 | $6.0Mbefore exit |
| GH Guardant Health Inc. | call | Sold out | 250,000 | $5.2Mbefore exit |
| CRSP Crispr Therapeutics AG | call | Sold out | 65,000 | $4.4Mbefore exit |
| IBRX Immunitybio Inc. | put | Sold out | 589,400 | $3.2Mbefore exit |
| SANA Sana Biotechnology Inc. | put | New | 521,000 | $2.8M |
| ESTA Establishment Labs Holdings | call | Sold out | 50,000 | $2.5Mbefore exit |
| TWST Twist Bioscience Corp. | call | New | 45,000 | $2.2M |
| AKRO Akero Therapeutics Inc. | call | Sold out | 75,000 | $1.9Mbefore exit |
| RAPT THERAPEUTICS INC | put | Reduce -5.6% | 545,000 | $1.7M |
| FULC Fulcrum Therapeutics Inc. | call | Reduce -9.1% | 250,000 | $1.6M |
| IMVT Immunovant Inc. | call | Reduce -62.4% | 54,300 | $1.4M |
| IOVA Iovance Biotherapeutics Inc. | put | New | 150,000 | $1.2M |
| PCVX Vaxcyte Inc. | call | New | 15,000 | $1.1M |
| ANVS Annovis Bio | put | Sold out | 72,900 | $868Kbefore exit |
| ALXO Alx Oncology Holdings Inc. | call | New | 100,000 | $603K |
| INSM Insmed Inc. | put | New | 8,700 | $583K |
| RAPT THERAPEUTICS INC | call | Sold out | 60,000 | $539Kbefore exit |
| GLYCOMIMETICS INC | put | Sold out | 142,300 | $427Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q1 2024 → Q2 2024
| ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27) | NOTE 1.000% 9/1 · principal | Add +50.0% | 15,000,000 | $16.2M |
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | Add +30.6% | 11,750,000 | $8.6M |
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | Add +9.1% | 11,450,000 | $8.1M |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | New | 9,750,000 | $6.3M |
| SAVAW Cassava Sciences Inc.-28 | *W EXP 11/15/202 | Sold out | 24,200 | $98Kbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $2.0B | ROIV, APGE, SYRE, XENE, ERAS |
| Q1 2026 | 90 | $1.7B | APGE, XENE, ERAS, INSM, ROIV |
| Q4 2025 | 80 | $1.3B | APGE, INSM, ABVX, VTYX, XENE |
| Q3 2025 | 80 | $1.0B | VRNA, INSM, SPY, XENE, MDGL |
| Q2 2025 | 71 | $648.9M | VRNA, INSM, XENE, ACLX, BPMC |
| Q1 2025 | 75 | $603.1M | XENE, APGE, VRNA, ACLX, ALKS |
| Q4 2024 | 68 | $588.3M | XENE, APGE, ACLX, ALKS, TEVA |
| Q3 2024 | 70 | $601.0M | XENE, APGE, NUVL, ACLX, ALKS |
| Q2 2024 | 78 | $576.0M | XENE, APGE, MDGL, ACLX, TEVA |
| Q1 2024 | 69 | $571.1M | APGE, XENE, MDGL, CRNX, AUTL |